

KLRK1 as a Prognostic Biomarker for Lung Adenocarcinoma Cancer

Yanan Zhang

Weifang Medical University

Zeyang Chen

Qingdao University

Guanqi Gao (✉ lyggao@163.com)

Linyi People's Hospital

Research Article

Keywords: lung cancer, KLRK1, diagnosis, prognosis, biomarker

Posted Date: August 11th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-786385/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License. [Read Full License](#)

Version of Record: A version of this preprint was published at Scientific Reports on February 7th, 2022. See the published version at <https://doi.org/10.1038/s41598-022-05997-z>.

Abstract

Background. Lung cancer is one of the most common malignancy worldwide and causes estimated 1.6 million deaths each year. Cancer immunosurveillance has been found to play an important role in lung cancer and may be related with its prognosis. KLRK1, encoding NKG2D, is a homodimeric lectin-like receptor. However, there has not been one research of KLRK1 as a biomarker in lung cancer.

Methods. Data including patients` clinical characteristics and RNAseq information of KLRK1 from TCGA were downloaded. A total of 1019 patients with lung cancer were included in this study, among which 407 patients were female and 611 patients were male. Evaluations of mRNA expression, diagnostic value by ROC (Receiver operating characteristic) curves and prognostic value by survival curve, Cox model and subgroup analysis were performed. The CCK-8 assay investigated the proliferation rate and the wound healing assay assessed the migratory ability in vitro.

Results. The expression of KLRK1 in tumor was lower than that in normal tissue. KLRK1 expression was associated with gender, histologic grade, stage, T classification and vital status. Patients with high KLRK1 expression presented an improved overall survival ($P=0.0036$) and relapse free survival ($P=0.0031$). KLRK1 was found to have significant prognostic value in lung adenocarcinoma ($P=0.015$), stage I/II ($P=0.03$), older patients ($P=0.0052$), and male ($P=0.0047$) by subgroup overall survival analysis, and in lung adenocarcinoma ($P=0.0094$), stage I/II ($P=0.0076$), older patients ($P=0.0072$), and male ($P=0.0033$) by subgroup relapse free survival analysis. Lung adenocarcinoma cancer patients with high KLRK1 expression presented an improved overall survival ($P=0.015$) and relapse free survival ($P=0.0094$). In vitro studies indicated that KLRK1 inhibited tumor cell proliferation and migration.

Conclusions. KLRK1 was an independent prognostic factor and high KLRK1 expression indicated a better overall and relapse free survival. KLRK1 may be a prognostic biomarker for lung adenocarcinoma cancer.

Introduction

Lung cancer is one of the most common malignancy worldwide and causes estimated 1.6 million deaths each year^{1,2}. Depending on stage and regional differences, the 5-year survival rate of lung cancer varied from 4–17%³. Lung cancer is classified into non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). SCLC only accounts for 15% of lung cancer cases, while the rest approximately 85% are NSCLC, among which lung adenocarcinoma and lung squamous cell carcinoma are the most common histological types^{1,2}.

Cancer immunosurveillance has been found to play an important role in lung cancer and may be related with its prognosis. Recently, the role of KLRK1 in cancer immunosurveillance and immune escape is widely studied^{4–6}. KLRK1, encoding NKG2D, is a homodimeric lectin-like receptor⁷. As a cytotoxic and co-stimulatory molecule on NK cells and T cells, KLRK1 is unique because it does not have any inhibitory isoforms^{8,9}. KLRK1 has two kinds of ligands, which belong to MIC and RAET1 gene family¹⁰. The ligands of KLRK1 are frequently expressed on primary tumor cells and KLRK1 was reported to play a role in the control of tumor and infection^{4,9}. Some studies have demonstrated the antitumor function of KLRK1, while some researchers argue that KLRK1 contributes to tumor growth in a model of inflammation-driven liver cancer^{11,12}. As Neal et

al. reviewed about developing biomarker-specific end points in lung cancer clinical trials, the exploration of biomarkers for a better diagnosis and prognosis is of great importance¹³. However, there has not been one research of KLRK1 as a biomarker in lung cancer.

In this study, expression of KLRK1 in patients with lung cancer was first evaluated. First, the relationship of KLRK1 and clinical features was examined. Then, the receiver operating characteristic (ROC) curves was plotted for analyzing the diagnostic value of KLRK1. To study the prognostic value of KLRK1, the survival package in R was used and Cox model was established, followed by evaluation of subgroups including different genders, different ages, and different stages.

Methods

Data mining

To collect original data from patients suffering from lung cancer, data mining was carried out. Specifically, we download data including patients' clinical characteristics and RNAseq information of KLRK1 from TCGA (The Cancer Genome Atlas) database by UCSC Xena. Given that all the data were open to public, no ethical approval was needed. A total of 1019 patients with lung cancer were included in this study, among which 407 patients were female and 611 patients were male.

The RNA expression of KLRK1 was shown in boxplots as center line represents median, top line and bottom line of the box represents upper and lower quartiles and vertical lines represents 95% confidence intervals (95% CI).

To study the diagnostic value of KLRK1 in patients with lung cancer, ROC (Receiver operating characteristic) curves was plotted by pROC package¹⁴. The calculated area under curves (AUC) indicated the diagnostic value. Furthermore, according to the identified threshold level of KLRK1, the patients were grouped into high expression group and low expression.

To study the prognostic value of KLRK1 in patients with lung cancer, the survival package in R was used and Cox model was established¹⁵. Evaluation of subgroups was performed as well.

Cell culture and cell transfection

A549 cell lines were purchased from American Tissue Culture Collection, and cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum at 37°C with 5% CO₂.

The KLRK1 sequence was amplified and inserted into pCMV vector (Beyotime). The transfection of KLRK1 over-expression or control plasmid was performed using Lipofectamine 3000 (Invitrogen).

Cell proliferation assay

The cells were treated with plasmids and cultured for 24 h. Then, 10 μ L of CCK-8 reagent was added and cultured for 20 min. A microplate reader was used to measure the absorbance at 490 nm. The cell viability was calculated relative to the untreated control.

To evaluate the cell viability, co-staining of calcein AM and PI was performed. The cells were seeded and incubated for 16 h. After different treatments for 24 h, the cells were stained and observed using a Nikon fluorescence microscope.

Wound healing assay

Wound-healing assays were performed as previously described¹⁶. The migration of cells toward the wound was photographed under a Nikon fluorescence microscope.

Statistical analysis

R version 3.5.2 packages (<https://www.R-project.org>) was used for bioinformatics analysis¹⁷. Data were presented using the ggplot2 package in R¹⁸. The Wilcoxon rank-sum test was used for comparison between two groups, and the Kruskal-Wallis test was used for comparison among three or more groups. For assessment of associations between KLRK1 expression and clinical parameters, the chi-squared test was used, and corrected by Fisher's exact test. Data from in vitro and in vivo experiments were analyzed by the Student's t-test (unpaired, two-tailed). $P < 0.05$ was statistical significance.

Results

Characteristics of patients with lung cancer

Clinical characteristics of the patients with lung cancer, including age, gender, histological type, stage, T classification, N classification, M classification, radiation therapy, residual tumor, vital status, sample type, KLRK1 expression, were shown in Table 1. The percentage of two histological types, lung adenocarcinoma (50.74%) and lung squamous cell carcinoma (49.26%), was close. About half of the patients were in stage I (51.13%). As for T, N, M classification, T2 (56.04%), N0 (63.98%), and M0 (74.39%) were highest among each classification. Most patients (99.80%) were primary tumor.

Table 1

Clinical characteristics of the patients with lung cancer

Characteristics	Number (%)
Age	
<55	109(10.70)
>=55	881(86.46)
NA	29(2.84)
Gender	
Female	407(39.94)
Male	611(59.96)
NA	1(0.10)
Histological type	
Lung adenocarcinoma	517(50.74)
Lung squamous cell carcinoma	502(49.26)
Stage	
I	521(51.13)
II	284(27.87)
III	168(16.49)
IV	33(3.24)
NA	13(1.28)
T classification	
T1	284(27.87)
T2	571(56.04)
T3	118(11.58)
T4	42(4.12)
TX	3(0.29)
NA	1(0.10)
N classification	
N0	652(63.98)
N1	227(22.28)
N2	114(11.19)
N3	7(0.69)

NX	17(1.67)
NA	2(0.20)
M classification	
M0	758(74.39)
M1	32(3.14)
MX	220(21.59)
NA	9(0.88)
Radiation therapy	
NO	782(76.74)
YES	110(10.79)
NA	127(12.46)
Residual tumor	
R0	743(72.91)
R1	25(2.45)
R2	8(0.79)
RX	48(4.71)
NA	195(19.14)
Vital status	
Deceased	404(39.65)
Living	614(60.26)
NA	1(0.10)
Sample type	
Primary tumor	1017(99.80)
Recurrent tumor	2(0.20)
KLRK1 expression	
High	701(68.79)
Low	318(31.21)

Note: NA: not available; X represents uncertain.

Low KLRK1 expression in tumor

As shown in Fig. 1, the expression of KLRK1 in tumor was lower than that in normal tissue ($P < 2.2 \times 10^{-16}$). The association of KLRK1 expression with clinical features, including histological type, sample type, age, gender, radiation therapy, was further evaluated. KLRK1 expression in lung squamous cell carcinoma was lower than that in lung adenocarcinoma ($P = 2.2 \times 10^{-5}$). KLRK1 expression in male was lower than that in female ($P = 3 \times 10^{-4}$). Other clinical features did not show statistical differences ($P > 0.05$).

Association of KLRK1 expression with stage, T classification, N classification, M classification, residual tumor and vital status was evaluated (Fig. 2). The KLRK1 expression got decreased progressively with higher stages ($P = 0.0015$) and T classification ($P = 2.6 \times 10^{-6}$). No significances were observed in N classification ($P = 0.200$), M classification ($P = 0.091$) and residual tumor ($P = 0.790$). The KLRK1 expression in living patients was a little higher than that in deceased patients ($P = 0.011$).

Diagnostic value of KLRK1 for lung cancer

As shown in Fig. 2, the ROC analysis was first performed in all lung cancer patients, indicating a modest diagnostic value with AUC of 0.789. Moreover, different stages of lung cancer were analyzed. It was suggested that the diagnostic value was increasing with stage getting higher from stage I (AUC=0.766) to stage II (AUC=0.797) to stage III (AUC=0.835) finally to stage IV (AUC=0.853) (Fig. 3).

Correlation of KLRK1 expression with clinical features

According to the threshold value ascertained by ROC analysis, patients were divided to two subgroups, high ($n = 701$) and low ($n = 318$) KLRK1 expression group. The relationship between the clinical features and KLRK1 expression in patients with lung cancer was shown in Table 2. KLRK1 expression was associated with gender ($P = 0.005$), histologic grade ($P = 0.001$), stage ($P = 0.001$), T classification ($P < 0.001$) and vital status ($P = 0.001$). No correlation was found between KLRK1 expression and age ($P = 0.431$), N classification ($P = 0.218$), M classification ($P = 0.383$), radiation therapy ($P = 0.399$), residual tumor ($P = 0.336$), and sample type ($P = 0.850$).

Table 2

Relationship between the clinical features and KLRK1 expression in patients with lung cancer

Clinical characteristics	Variable	Number of patients	KLRK1				χ^2	P value
			High	%	Low	%		
Age	<55	109	71	(10.41)	38	(12.34)	0.620	0.431
	>=55	881	611	(89.59)	270	(87.66)		
Gender	Female	407	301	(42.94)	106	(33.44)	7.819	0.005
	Male	611	400	(57.06)	211	(66.56)		
Histological type	Lung adenocarcinoma	517	381	(54.35)	136	(42.77)	11.285	0.001
	Lung squamous cell carcinoma	502	320	(45.65)	182	(57.23)		
Stage	I	521	386	(55.86)	135	(42.86)	15.336	0.001
	II	284	181	(26.19)	103	(32.70)		
	III	168	102	(14.76)	66	(20.95)		
	IV	33	22	(3.18)	11	(3.49)		
T classification	T1	284	229	(32.67)	55	(17.35)	29.391	<0.001
	T2	571	373	(53.21)	198	(62.46)		
	T3	118	69	(9.84)	49	(15.46)		
	T4	42	27	(3.85)	15	(4.73)		
	TX	3	3	(0.43)	0	(0)		
N classification	N0	652	461	(65.86)	191	(60.25)	5.610	0.218
	N1	227	146	(20.86)	81	(25.55)		
	N2	114	75	(10.71)	39	(12.30)		
	N3	7	4	(0.57)	3	(0.95)		
	NX	17	14	(2.00)	3	(0.95)		
M classification	M0	758	516	(74.03)	242	(77.32)	1.904	0.383
	M1	32	21	(3.01)	11	(3.51)		
	MX	220	160	(22.96)	60	(19.17)		
Radiation therapy	NO	782	540	(88.38)	242	(86.12)	0.711	0.399
	YES	110	71	(11.62)	39	(13.88)		

Residual tumor	R0	743	513	(90.80)	230	(88.8)	3.305	0.336
	R1	25	14	(2.48)	11	(4.25)		
	R2	8	4	(0.71)	4	(1.54)		
	RX	48	34	(6.02)	14	(5.41)		
Vital status	Deceased	404	253	(36.09)	151	(47.63)	11.673	0.001
	Living	614	448	(63.91)	166	(52.37)		
Sample type	Primary tumor	1017	699	(99.71)	318	(100)	0.036	0.850
	Recurrent tumor	2	2	(0.29)	0	(0)		

Note: X represents uncertain.

Overall survival and relapse free survival of KLRK1 for lung cancer

Given that KLRK1 was correlated with survival, the prognostic value of KLRK1 was further studied. As shown in Fig. 4, lung cancer patients with high KLRK1 expression presented an improved overall survival ($P=0.0036$) and relapse free survival ($P=0.0031$). As shown in Fig. 5, lung adenocarcinoma cancer patients with high KLRK1 expression presented an improved overall survival ($P=0.015$) and relapse free survival ($P=0.0094$). But no significances were found in lung squamous cell cancer patients with high KLRK1 expression.

Subgroup analysis of KLRK1 for lung cancer`s overall survival

By overall survival analysis of subgroups (Fig. 6, S1-2), KLRK1 was found to have significant prognostic value in lung adenocarcinoma ($P=0.015$), stage I/II ($P=0.03$), older patients ($P=0.0052$), and male ($P=0.0047$). For lung adenocarcinoma cancer, KLRK1 was found to have significant prognostic value in stage I/II ($P=0.049$), older patients ($P=0.0064$), and male ($P=0.013$).

Subgroup analysis of KLRK1 for lung cancer`s relapse free survival

By relapse free survival analysis of subgroups (Fig. 7, S3-4), KLRK1 was found to have significant prognostic value in lung adenocarcinoma ($P=0.0094$), stage I/II ($P=0.0076$), older patients ($P=0.0072$), and male ($P=0.0033$). For lung adenocarcinoma cancer, KLRK1 was found to have significant prognostic value in stage I/II ($P=0.0025$), and older patients ($P=0.012$).

KLRK1 is an independent risk factor for lung cancer`s overall survival

The univariate Cox model of overall and relapse free survival in patients with lung cancer was established (Table 3-4, S1), and the multivariate analysis of overall and relapse free survival in patients with lung cancer was further performed (Table 5-6, S2).

As shown in Table 3, no obvious differences were observed in age (P=0.867), gender (P=0.201), histological type (P=0.282), M classification (P=0.220), and radiation therapy (P=0.983). T classification (P<0.001), N classification (P<0.001), residual tumor (P=0.016), stage (P<0.001) and KLRK1 expression (P=0.004) showed significant differences for lung cancer. As shown in Table 4, T classification (P<0.001), N classification (P<0.001), M classification (P=0.029), residual tumor (P=0.037), stage (P<0.001) and KLRK1 expression (P=0.016) showed significant differences for lung adenocarcinoma cancer. As shown in Table 5, T classification (HR=1.18; 95% CI: 1.02-1.36; P=0.025) and stage (HR=1.34; 95% CI: 1.14-1.57; P<0.001) were risk factors for lung cancer.

Table 3

Univariate analysis of overall and relapse free survival in patients with lung cancer

	Overall survival			Relapse free survival		
	Hazard Ratio	95%CI	P value	Hazard Ratio	95%CI	P value
Age	1.03	0.74-1.43	0.867	0.95	0.63-1.43	0.819
Gender	1.14	0.93-1.40	0.201	0.94	0.73-1.20	0.613
Histological type	1.12	0.91-1.36	0.282	0.63	0.49-0.82	<0.001
T classification	1.42	1.25-1.61	<0.001	1.35	1.14-1.59	<0.001
N classification	1.39	1.22-1.57	<0.001	1.41	1.20-1.65	<0.001
M classification	1.16	0.91-1.49	0.220	0.83	0.62-1.11	0.210
Radiation therapy	1.00	0.79-1.27	0.983	1.76	1.32-2.35	<0.001
Residual tumor	1.17	1.03-1.33	0.016	1.29	1.11-1.49	0.001
Stage	1.48	1.33-1.64	<0.001	1.41	1.23-1.62	<0.001
KLRK1 expression	0.74	0.60-0.91	0.004	0.68	0.52-0.88	0.003

KLRK1 is an independent risk factor for lung cancer`s relapse free survival

As shown in Table 3, no obvious differences were observed in age (P=0.819), gender (P=0.613), and M classification (P=0.210). Histological type (P<0.001), T classification (P<0.001), N classification (P<0.001), radiation therapy (P<0.001), residual tumor (0.001), stage (P<0.001) and KLRK1 expression (P=0.003) showed significant differences. As shown in Table 4, stage (P<0.001) showed significant differences for lung adenocarcinoma cancer. As shown in Table 5, T classification (HR=1.22; 95% CI: 1.01-1.47; P=0.040), radiation therapy (HR=1.42; 95% CI: 1.06-1.91; P=0.018) and residual tumor (HR=1.23; 95% CI: 1.07-1.42; P=0.004) were risk factors for lung cancer.

Table 4

Univariate analysis of overall and relapse free survival in patients with lung adenocarcinoma cancer

	Overall survival			Relapse free survival		
	Hazard Ratio	95%CI	P value	Hazard Ratio	95%CI	P value
Age	0.82	0.55-1.22	0.322	-	-	-
Gender	1.05	0.78-1.4	0.760	-	-	-
T classification	1.52	1.26-1.82	<0.001	1.16	0.96-1.4	0.132
N classification	1.67	1.41-1.97	<0.001	1.15	0.92-1.44	0.228
M classification	1.4	1.04-1.9	0.029	0.93	0.68-1.28	0.662
Radiation therapy	1.25	0.89-1.75	0.199	-	-	-
Residual tumor	1.2	1.01-1.42	0.037	1.14	0.96-1.35	0.150
Stage	1.68	1.47-1.93	<0.001	1.51	1.21-1.89	<0.001
KLRK1	0.69	0.51-0.93	0.016	0.78	0.57-1.07	0.129

KLRK1 inhibits lung cancer cell proliferation and migration *in vitro*

We further studied the effect of KLRK1 on cells by overexpressing KLRK1 in lung cancer A549 cell lines. The CCK-8 assay showed that KLRK1 upregulation significantly inhibited cell proliferation (P < 0.05; Fig. 8A). Compared with control group, KLRK1 increased the percentage of dead cells by live/dead staining (Fig. 8B). KLRK1 decreased the migration distance of cancer cell (P < 0.05; Fig. 8C and 8D).

Table 5

Multivariate analysis of overall survival and relapse free survival in patients with lung cancer

	Overall survival			Relapse-free survival		
	Hazard Ratio	95%CI	P value	Hazard Ratio	95%CI	P value
Histological type	-	-	-	0.58	0.45-0.76	<0.001
T classification	1.18	1.02-1.36	0.025	1.22	1.01-1.47	0.040
N classification	-	-	-	1.11	0.89-1.4	0.343
Radiation therapy	-	-	-	1.42	1.06-1.91	0.018
Residual tumor	1.13	0.99-1.28	0.067	1.23	1.07-1.42	0.004
Stage	1.34	1.14-1.57	<0.001	1.16	0.93-1.43	0.183
KLRK1	0.79	0.64-0.97	0.025	0.74	0.57-0.96	0.022

Table 6

Multivariate analysis of overall survival and relapse free survival in patients with lung adenocarcinoma cancer

	Overall survival			Relapse free survival		
	Hazard Ratio	95%CI	P value	Hazard Ratio	95%CI	P value
T classification	1.39	1.13-1.71	0.002	1.18	0.94-1.49	0.155
N classification	1.45	1.2-1.76	<0.001	1.12	0.85-1.48	0.410
Radiation therapy	1.97	1.37-2.82	<0.001	1.62	1.12-2.35	0.010
Residual tumor	1.20	1.01-1.43	0.035	1.16	0.98-1.38	0.088
Stage	1.44	1.23-1.7	<0.001	1.17	0.91-1.51	0.209
KLRK1	0.64	0.45-0.9	0.010	0.74	0.52-1.06	0.099

Discussion

Lung cancer is one of the most common malignancy with poor prognosis worldwide. Many researches have working on mining novel prognostic biomarker in different types of cancer¹⁹⁻³⁵. However, little is done in the field of lung cancer. In this bioinformatics study, KLRK1 was found to lower expressed in lung cancer compared with normal lung tissue. KLRK1 expression was associated with gender, histologic grade, stage, T classification and vital status. Moreover, KLRK1 presented a moderate diagnostic value for lung cancer.

Recently, research about biomarkers by data mining is popular^{19,20,22,23,26,29,35-39}. Although some protein blood biomarkers have already been put into clinical practice, the ability of their diagnosis and prognosis is limited and the exploration of biomarkers for lung cancer is ongoing.¹³. CEA (carcinoembryonic antigen) and

CTC (Circulating tumor cells) are used in some lung cancers^{40,41}. Also, there are studies reporting some novel biomarkers. Jiang et al. found thymidine kinase 1 combined with CEA, CYFRA21-1 and NSE improved its diagnostic value for lung cancer⁴². Yang et al. compared the different value of combination in CEA, CA125 (carbohydrate antigen 125), CY211 (cytokeratin 19 fragment), NSE (neuron-specific enolase), and SCC (squamous cell carcinoma antigen)⁴³. Tang et al. identified HSP70 (circulating heat shock protein 70) as a novel biomarker for early diagnosis of lung cancer⁴⁴. In this study, we first found KLRK1 as a prognostic biomarker for lung cancer.

Researches of biomarkers for lung cancer are not only limited in prognosis but also in diagnosis. Wu et al. found UCK2 (Uridine-cytidine kinase 2) as a potential diagnostic and prognostic biomarker for lung cancer, and identified UCK2 highly expressed in stage IA lung cancer with AUC > 0.9⁴⁵. Jiang et al. reported a diagnostic value of circulating lncRNA XLOC_009167 with AUC of 0.7398⁴⁶. Similarly, we found the KLRK1 presented a promising diagnostic value in lung cancer, especially advanced stages. In comparison of lung cancer vs. tumor, the AUC could get into 0.789, indicating a relatively high diagnostic value of KLRK1 as a biomarker for lung cancer.

KLRK1 is an immunoreceptor binding to a variety of cell surface glycoproteins distantly related to MHC class I molecules⁴⁷. A recent study conducted by Shi et al. reported the up-regulation of KLRK1-activating receptors that recognize lung cancer could facilitate the clearance of lung cancer⁴⁸. Their results confirmed the role of KLRK1 in changing state of NK cells, leading to the control of lung cancer through immunosurveillance. Paczulla et al. reported the absence of KLRK1 ligand mediated the immune evasion of leukaemia stem cells²⁹. Dong et al. found T cells expressing KLRK1 chimeric antigen receptors could efficiently eliminate glioblastoma and cancer stem cells³³. From our results, high KLRK1 expression is associated with a better overall and relapse free survival, which may attributes to the immunosurveillance of KLRK1 therefore suppressing the proliferation and metastasis of lung cancer⁴. Of note, our results showed the significances of KLRK1 in both overall survival and relapse free survival in lung cancer.

Our research first suggested the diagnostic and prognostic value of KLRK1 for lung cancer. However, the major limitation is that this study analyzed the data from a single database by data mining. Further verifications in different areas and populations are required. Besides, *in vivo* function experiments and exploration of its molecular mechanism would further illuminate the role of KLRK1 in lung cancer.

Conclusions

In conclusion, KLRK1 was lower expressed in lung cancer in comparison with normal lung tissue. KLRK1 expression was associated with gender, histologic grade, stage, T classification and vital status. KLRK1 had a diagnostic value for lung adenocarcinoma cancer. KLRK1 was an independent prognostic factor and high KLRK1 expression indicated a better overall and relapse free survival. KLRK1 may be a novel biomarker for lung adenocarcinoma cancer.

Declarations

Author Contribution

YZ contributed to the study design and wrote the manuscript. ZC contributed to the data evaluation and revised the manuscript. GG supervised the study and extensively revised the manuscript.

Disclosure

The authors have no conflicts of interest to declare.

References

1. Herbst, R. S., Morgensztern, D. & Boshoff, C. The biology and management of non-small cell lung cancer. *Nature. Jan*, **24** (7689), 446–454 (2018).
2. Gridelli, C. *et al.* Non-small-cell lung cancer. *Nature reviews. Disease primers. May*, **21**, 115009 (2015).
3. Fred, R. *et al.* Luis Paz-Ares. Lung cancer: current therapies and new targeted treatments. *lancet*, **389**, 299–311 (2017).
4. Ljunggren, H. G. Cancer immunosurveillance: NKG2D breaks cover. *Immunity. Apr*, **28** (4), 492–494 (2008).
5. Schmiedel, D. & Mandelboim, O. NKG2D Ligands-Critical Targets for Cancer Immune Escape and Therapy. *Frontiers in immunology*, **9**, 2040 (2018).
6. Ding, H., Yang, X. & Wei, Y. Fusion Proteins of NKG2D/NKG2DL in Cancer Immunotherapy. *International journal of molecular sciences. Jan7* 2018;19(1).
7. Lanier, L. L. Up on the tightrope: natural killer cell activation and inhibition. *Nature immunology. May*, **9** (5), 495–502 (2008).
8. Antoun, A. *et al.* The genotype of RAET1L (ULBP6), a ligand for human NKG2D (KLRK1), markedly influences the clinical outcome of allogeneic stem cell transplantation. *British journal of haematology. Dec*, **159** (5), 589–598 (2012).
9. Jelencic, V. *et al.* NK cell receptor NKG2D sets activation threshold for the NCR1 receptor early in NK cell development. *Nature immunology. Oct*, **19** (10), 1083–1092 (2018).
10. JrMI, D. C. *et al.* and N. Jan Chalupny. ULBPs, Novel MHC Class I-Related Molecules, Bind to CMV Glycoprotein UL16 and Stimulate NK Cytotoxicity through the NKG2D Receptor. *Immunit*, **14**, 123–133 (2001).
11. Sheppard, S., Ferry, A., Guedes, J. & Guerra, N. The Paradoxical Role of NKG2D in Cancer Immunity. *Frontiers in immunology*, **9**, 1808 (2018).
12. Duan, S. *et al.* Natural killer group 2D receptor and its ligands in cancer immune escape. *Molecular cancer. Feb*, **27** (1), 29 (2019).
13. Neal, J. W., Gainor, J. F. & Shaw, A. T. Developing biomarker-specific end points in lung cancer clinical trials. *Nature reviews. Clinical oncology. Mar*, **12** (3), 135–146 (2015).

14. Robin, X. *et al.* pROC: an open-source package for R and S + to analyze and compare ROC curves. *BMC Bioinformatics*. Mar, **17**, 1277 (2011).
15. Moreno-Betancur, M., Sadaoui, H., Piffaretti, C. & Rey, G. Survival Analysis with Multiple Causes of Death: Extending the Competing Risks Model. *Epidemiology*. Jan, **28** (1), 12–19 (2017).
16. Yan, F. *et al.* A regulatory circuit composed of DNA methyltransferases and receptor tyrosine kinases controls lung cancer cell aggressiveness. *Dec*, **14** (50), 6919–6928 (2017).
17. Team, R. D. C. J. C. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 2009;14:12–21.
18. Wickham, H. Ggplot2:elegant graphics for data analysis. *Journal of the Royal Statistical Society*, **174** (1), 245–246 (2011).
19. Cai, H. *et al.* Low CYP24A1 mRNA expression and its role in prognosis of breast cancer. *Sci Rep*. Sep, **23** (1), 13714 (2019).
20. Cui, Y., Jiao, Y., Wang, K., He, M. & Yang, Z. A new prognostic factor of breast cancer: High carboxyl ester lipase expression related to poor survival. *Cancer Genet*. Sep, **18**, 23954–23961 (2019).
21. Hou, L. *et al.* ATP binding cassette subfamily B member 9 (ABCB9) is a prognostic indicator of overall survival in ovarian cancer. *Medicine (Baltimore)*. May, **98** (19), e15698 (2019).
22. Jiao, Y., Fu, Z., Li, Y., Meng, L. & Liu, Y. High EIF2B5 mRNA expression and its prognostic significance in liver cancer: a study based on the TCGA and GEO database. *Cancer management and research*, **10**, 6003–6014 (2018).
23. Jiao, Y., Fu, Z., Li, Y., Zhang, W. & Liu, Y. Aberrant FAM64A mRNA expression is an independent predictor of poor survival in pancreatic cancer. *PloS one*, **14** (1), e0211291 (2019).
24. Jiao, Y. *et al.* OGDHL Expression as a Prognostic Biomarker for Liver Cancer Patients. *Dis Markers*, **2019**, 9037131 (2019).
25. Jiao, Y., Li, Y., Ji, B., Cai, H. & Liu, Y. Clinical Value of lncRNA LUCAT1 Expression in Liver Cancer and its Potential Pathways. *J Gastrointestin Liver Dis*. Dec, **9** (4), 439–447 (2019).
26. Jiao, Y., Li, Y., Jiang, P., Han, W. & Liu, Y. PGM5: a novel diagnostic and prognostic biomarker for liver cancer. *PeerJ*, **7**, e7070 (2019).
27. Jiao, Y., Li, Y., Liu, S., Chen, Q. & Liu, Y. ITGA3 serves as a diagnostic and prognostic biomarker for pancreatic cancer. *OncoTargets and therapy*, **12**, 4141–4152 (2019).
28. Jiao, Y., Li, Y., Lu, Z. & Liu, Y. High Trophinin-Associated Protein Expression Is an Independent Predictor of Poor Survival in Liver Cancer. *Digestive diseases and sciences*. Jan, **64** (1), 137–143 (2019).
29. Paczulla, A. M. *et al.* Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion. *Nature*. Aug, **572** (7768), 254–259 (2019).
30. Li, Y., Jiao, Y., Li, Y. & Liu, Y. Expression of La Ribonucleoprotein Domain Family Member 4B (LARP4B) in Liver Cancer and Their Clinical and Prognostic Significance. *Dis Markers*, **2019**, 1569049 (2019).
31. Li, Y., Jiao, Y., Luo, Z., Li, Y. & Liu, Y. High peroxidasin-like expression is a potential and independent prognostic biomarker in breast cancer. *Medicine (Baltimore)*. Nov, **98** (44), e17703 (2019).

32. Nie, Y., Jiao, Y., Li, Y. & Li, W. Investigation of the Clinical Significance and Prognostic Value of the lncRNA ACVR2B-As1 in Liver Cancer. *BioMed Research International*, **2019**, 13 (2019).
33. Yang, D. *et al.* T cells expressing NKG2D chimeric antigen receptors efficiently eliminate glioblastoma and cancer stem cells. *Journal for immunotherapy of cancer*. Jul, **9** (1), 171 (2019).
34. Zhang, X., Cui, Y., He, M., Jiao, Y. & Yang, Z. Lipocalin-1 Expression as a Prognosticator Marker of Survival in Breast Cancer Patients. *Breast Care*. 2019.
35. Zhao, Y. C. *et al.* Elevated high mobility group A2 expression in liver cancer predicts poor patient survival. *Rev Esp Enferm Dig*. Dec, **11**, 112 (2019).
36. Fu, Z. *et al.* PES1 In Liver Cancer: A Prognostic Biomarker With Tumorigenic Roles. *Cancer management and research*, **11**, 9641–9653 (2019).
37. Jiao, Y. *et al.* OGDHL Expression as a Prognostic Biomarker for Liver Cancer Patients %J. *Dis. Markers*, **2019**, 9 (2019).
38. Li, Y., Jiao, Y., Luo, Z., Li, Y. & Liu, Y. High peroxidase-like expression is a potential and independent prognostic biomarker in breast cancer. 2019;98(44):e17703.
39. Zhou, L. L. *et al.* Differentially expressed long noncoding RNAs and regulatory mechanism of LINC02407 in human gastric adenocarcinoma. *World J Gastroenterol*. Oct, **21** (39), 5973–5990 (2019).
40. Krebs, M. G. *et al.* Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. *Journal of clinical oncology: official journal of the American Society of Clinical Oncology*. Apr, **20** (12), 1556–1563 (2011).
41. Grunnet, M. & Sorensen, J. B. Carcinoembryonic antigen (CEA) as tumor marker in lung cancer. *Lung cancer*. May, **76** (2), 138–143 (2012).
42. Jiang, Z. F., Wang, M. & Xu, J. L. Thymidine kinase 1 combined with CEA, CYFRA21-1 and NSE improved its diagnostic value for lung cancer. *Life sciences*. Feb, **1**, 1941–1946 (2018).
43. Yang, Q., Zhang, P., Wu, R., Lu, K. & Zhou, H. Identifying the Best Marker Combination in CEA, CA125, CY211, NSE, and SCC for Lung Cancer Screening by Combining ROC Curve and Logistic Regression Analyses: Is It Feasible? *Disease markers*, **2018**, 2082840 (2018).
44. Tang, T., Yang, C., Brown, H. E. & Huang, J. Circulating Heat Shock Protein 70 Is a Novel Biomarker for Early Diagnosis of Lung Cancer. *Disease markers*, **2018**, 6184162 (2018).
45. Wu, Y. *et al.* Uridine-cytidine kinase 2 (UCK2): A potential diagnostic and prognostic biomarker for lung cancer. *Cancer science*. Sep, **110** (9), 2734–2747 (2019).
46. Jiang, N. *et al.* Circulating lncRNA XLOC_009167 serves as a diagnostic biomarker to predict lung cancer. *Clinica chimica acta; international journal of clinical chemistry*. Nov, **486**, 26–33 (2018).
47. Lazarova, M. & Steinle, A. The NKG2D axis: an emerging target in cancer immunotherapy. *Apr*, **23** (4), 281–294 (2019).
48. Lei Shi, K. L. *et al.* g, Michael G. Brown, h, and Alexander Sasha Krupnick. Modulation of NKG2D, NKp46, and Ly49C/I facilitates natural killer cell-mediated control of lung cancer. *PNAS*. 2018;115(46):11808–11813.

Figures




Figure 1

KLRK1 expression in lung cancer. Expression of KLRK1 grouped by (A) tumor vs. normal tissue, (B) histological type, (C) sample type, (D) age, (E) gender, and (E) radiation therapy.




Figure 2

KLRK1 expression in lung cancer. Expression of KLRK1 grouped by (A) stage, (B) T classification, (C) N classification, (D) M classification, (E) residual tumor and (F) vital status.




Figure 3

ROC (Receiver operating characteristic) curves of KLRK1 expression in patients with lung cancer. (A) Normal vs. overall, (B) stage I, (C) stage II, (D) stage III and (E) stage IV tumor.




Figure 4

Relationship of KLRK1 expression with (A) overall and (B) relapse free survival in all patients with lung cancer.




Figure 5

Relationship of KLRK1 expression with (A) overall and (B) relapse free survival in patients with lung adenocarcinoma cancer, and (C) overall and (D) relapse free survival in patients with lung squamous cell cancer.




Figure 6

Relationship of KLRK1 expression with overall survival in all patients with lung cancer in (A) lung adenocarcinoma, (B) lung squamous cell carcinoma, (C) stage I/II, (D) stage III/IV, (E) older patients, (F) younger patients, (G) female and (H) male.




Figure 7

Relationship of KLRK1 expression with relapse free survival in all patients with lung cancer in (A) lung adenocarcinoma, (B) lung squamous cell carcinoma, (C) stage I/II, (D) stage III/IV, (E) older patients, (F) younger patients, (G) female and (H) male.




Figure 8

The effect of KLRK1 in lung cancer A549 cell lines. (A) The CCK-8 assay; (B) live/dead staining; (C) The migration and (D) migration distance.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [supplementaryfiguresandtables.docx](#)